Purdue Pharma Settlement: $7.4B Opioid Deal Expands
- A sweeping $7.4 billion settlement has been agreed upon with Purdue Pharma and the sackler family, resolving claims from 55 attorneys general nationwide regarding the opioid crisis.
- The settlement, if approved by the courts, will end the Sacklers' control of Purdue Pharma, the maker of OxyContin, and prevent the family from future opioid sales in...
- New York Attorney general Letitia James stated that the Sacklers prioritized profits over people for decades, playing a notable role in fueling the opioid addiction and overdose epidemic.
The opioid crisis sees a major shift as Purdue Pharma and the Sackler family reach a $7.4 billion settlement, paving the way for victim compensation. This landmark agreement,involving 55 attorneys general,addresses the devastating impact of the opioid epidemic. The settlement also removes the Sacklers from control of Purdue Pharma, ending their role in opioid sales. Funds, distributed over 15 years, will help states combat the crisis. New York’s Attorney General emphasizes the funds’ goal to mitigate the damage. For details on state-specific allocations, and Purdue’s future role, visit News Directory 3.discover what’s next in this evolving story.
Purdue Pharma Opioid Settlement Reaches $7.4 Billion
Updated June 17, 2025
A sweeping $7.4 billion settlement has been agreed upon with Purdue Pharma and the sackler family, resolving claims from 55 attorneys general nationwide regarding the opioid crisis. This agreement builds upon an initial settlement supported by 15 states in January,with an additional 34 states,five territories,and Washington,D.C.,now on board.
The settlement, if approved by the courts, will end the Sacklers’ control of Purdue Pharma, the maker of OxyContin, and prevent the family from future opioid sales in the U.S. Oklahoma previously reached a separate $270 million settlement in 2019.
New York Attorney general Letitia James stated that the Sacklers prioritized profits over people for decades, playing a notable role in fueling the opioid addiction and overdose epidemic. She added that while no amount of money can fully repair the damage, these funds will help communities combat the opioid crisis.
The funds will be distributed over 15 years, with over half expected to be paid out in the initial years. The Sacklers will make an initial payment of $1.5 billion,and Purdue will contribute approximately $900 million. Subsequent payments from the Sacklers include $500 million after one year, another $500 million after two years, and $400 million after three years.
The settlement amounts vary by state. California is expected to receive up to $440 million, Colorado around $75 million, New Jersey up to $124.5 million, and New York up to $250 million.
Purdue Pharma stated that the settlement funds will be used to compensate victims, abate the opioid crisis, and provide medicines for opioid use disorder and overdose rescue. The company also expressed gratitude for the hard work of the state attorneys general and creditors.
The agreement leaves Purdue in bankruptcy, subject to oversight, and prohibits the company from lobbying or marketing opioids. A board of trustees, appointed by the involved states, will oversee the company and determine its future.
A prior Purdue bankruptcy settlement was rejected by the U.S. Supreme Court last year. The justices ruled that the Sackler family could not be shielded from civil claims related to the opioid epidemic. The original settlement would have required the Sacklers and Purdue to pay over $4.5 billion.
What’s next
The court’s approval of this settlement marks a significant step in addressing the opioid crisis, with significant funds